iwNHL 2015 Highlights

October 2nd – 4th 2015

The 13th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, held in Baveno, Italy, provided a forum for many of the world’s leading researchers in non-Hodgkin lymphoma (NHL) and related disorders to share their perspectives on the evolving understanding of NHL in a clinical context.

To view all videos from the event please click here

Day 1 highlights

John Gribben and Anas Younes

John Gribben, MD, DSc, FRCPath, FRCP FMedSci, of Barts and The London School of Medicine and Dentistry, London, UK, chairs a discussion with Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, on the highlights from the first day of the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting.

Discussion topics include advances in targeting the tumor microenvironment through immune checkpoint inhibitors, alone or in combination, as a therapeutic strategy for non-Hodgkin lymphoma; and the efforts and challenges to further understand T-cell and B-cell lymphoma biology and underlying molecular events for the development of personalized medicine.

Day 2 highlights

CAR T-cell therapy for non-Hodgkin lymphoma

John Gribben, MD, DSc, FRCPath, FRCP FMedSci, of Barts and The London School of Medicine and Dentistry, London, UK, chairs a discussion with Wyndham Wilson, MD, PhD, of the National Cancer Institute, Bethesda, MD, on the highlights from the second day of the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting. They explain the challenges, including the need to overcome clinical toxicities, to chimeric antigen receptor (CAR)-T cell therapy for the treatment of patients with non-Hodgkin lymphoma.

Bortezomib, proteasome inhibitor, for B-cell lymphoma

John Gribben, MD, DSc, FRCPath, FRCP FMedSci, of Barts and The London School of Medicine and Dentistry, London, UK, chairs a discussion with Wyndham Wilson, MD, PhD, of the National Cancer Institute, Bethesda, MD, on the highlights from the second day of the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting. They evaluate the clinical data supporting the use of bortezomib, a proteasome inhibitor, for the treatment of patients with diffuse large B-cell lymphoma and mantle cell lymphoma.

Lenalidomide and ibrutinib for DLBCL

John Gribben, MD, DSc, FRCPath, FRCP FMedSci, of Barts and The London School of Medicine and Dentistry, London, UK, chairs a discussion with Wyndham Wilson, MD, PhD, of the National Cancer Institute, Bethesda, MD, on the highlights from the second day of the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting. They discuss a phase 1b/2 clinical trial that was designed to assess the safety and efficacy of ibrutinib and lenalidomide in combination with chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

PI3K inhibitors

John Gribben, MD, DSc, FRCPath, FRCP FMedSci, of Barts and The London School of Medicine and Dentistry, London, UK, chairs a discussion with Wyndham Wilson, MD, PhD, on the highlights from the second day of the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting. They review the clinical development of inhibitors targeting the phosphoinositide 3-kinase (PI3K) pathway, as single agents and in combination with other therapies, for the treatment of patients with non-Hodgkin lymphoma.

Ibrutinib for diffuse large B-cell lymphoma

John Gribben, MD, DSc, FRCPath, FRCP FMedSci, of Barts and The London School of Medicine and Dentistry, London, UK, chairs a discussion with Wyndham Wilson, MD, PhD, of the National Cancer Institute, Bethesda, MD, on highlights from the second day of the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting. They discuss how improved understanding of B-cell biology may be used to inform treatment decisions, including targeting B-cell receptor signaling with ibrutinib for the treatment of patients with diffuse large B-cell lymphoma.

Other videos from the event

Emerging monoclonal antibodies for lymphoma therapy

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Thomas J. Kipps, MD, PhD, of the University of California, San Diego, San Diego, CA, discusses novel monoclonal antibodies against CD20, including rituximab, ofatumumab and obinutuzumab, that are progressing in clinical development as single agents and in combination for the treatment of patients with non-Hodgkin lymphoma.

Using B-cell biology to inform therapy

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Michael Pfreundschuh, MD, of Universitaetsklinikum des Saarlandes, Homburg, Germany, chairs a discussion with Randy Gascoyne, MD, of the BC Cancer Research Centre, Vancouver, British Columbia, Canada, and Kieron M. Dunleavy, MD, National Cancer Institute, Bethesda, MD. They summarise the biological understanding of the molecular subtypes of diffuse large B-cell lymphoma (DLBCL), including germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, and primary mediastinal B-cell lymphoma (PMBL), with an emphasis on diagnostic and rational therapeutic approaches for the management of these patients.

Combination studies with venetoclax (ABT-199), BCL-2 inhibitor, for non-Hodgkin lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Michael E. Williams, MD, of the University of Virginia School of Medicine, Charlottesville, VA, discusses the clinical development of venetoclax, a selective BCL-2 inhibitor, for the treatment of patients with non-Hodgkin lymphoma. Dr Williams focuses on a phase 1 clinical trial that was designed to determine the optimal dosing scheme for the combination of venetoclax and ibrutinib for the treatment of relapsed or refractory mantle cell lymphoma.

Future directions for the management of non-Hodgkin lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, chairs a discussion with Steven T. Rosen, MD, of City of Hope, Duarte, CA, on recent advances in the biological understanding of non-Hodgkin lymphoma and the continued need to optimize the delivery of new therapies for individual patients.

Biology of diffuse large B-cell lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Catherine M. Bollard, MBChB, MD, FRACP, FRCPA, of Children's National Health System and The George Washington University, Washington, DC, chairs a discussion with Wyndham Wilson, MD, PhD, of the National Cancer Institute, Bethesda, MD, Louis M. Staudt, MD, PhD, of the National Cancer Institute, Bethesda, MD, and Riccardo Dalla-Favera, MD, of the Institute of Cancer Genetics, Columbia University, New York, NY, on the clinical implications of the current understanding of the biology of B cells and diffuse large B-cell lymphoma (DLBCL) subtypes, including activated B-cell-like (ABC) DLBCL and germinal-center B-cell-like (GCB) DLBCL. They explain that these subtypes are characterised by significant differences in outcomes and responses to treatment.

Novel therapeutic combinations for relapsed/refractory T-cell lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Francine M. Foss, MD, of the Yale University School of Medicine, New Haven, CT, chairs a discussion with Laurence de Leval, MD, PhD, of Institut universitaire de pathologie, Lausanne, Switzerland, Francesco d'Amore, MD, PhD of Aarhus University Hospital, Aarhus, Denmark, and Owen A. O'Connor, MD, PhD, Columbia University, New York, NY. Dr O’Connor summarises the current evidence on novel therapies, with an emphasis on combination regimens, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

Improving treatment strategies for T-cell lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Francine M. Foss, MD, of the Yale University School of Medicine, New Haven, CT, chairs a discussion with Laurence de Leval, MD, PhD, of Institut universitaire de pathologie, Lausanne, Switzerland, Francesco d'Amore, MD, PhD of Aarhus University Hospital, Aarhus, Denmark, and Owen A. O'Connor, MD, PhD, Columbia University, New York, NY. Professor d’Amore highlights current frontline management approaches and clinical trial data supporting the use of new approaches for patients with peripheral T-cell lymphoma.

Molecular biology of T-cell lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Francine M. Foss, MD, of the Yale University School of Medicine, New Haven, CT, chairs a discussion with Laurence de Leval, MD, PhD, of Institut universitaire de pathologie, Lausanne, Switzerland, Francesco d'Amore, MD, PhD of Aarhus University Hospital, Aarhus, Denmark, and Owen A. O'Connor, MD, PhD, Columbia University, New York, NY. Professor de Leval highlights recent discoveries in the molecular mechanisms of T-cell lymphoma development as well as the potential application of new biological markers for this patient population.

Ibrutinib, Bruton’s tyrosine kinase inhibitor, for non-Hodgkin lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Thomas J. Kipps, MD, PhD, of the University of California, San Diego, San Diego, CA, discusses the currently available data on the safety and efficacy of ibrutinib, a first-in-class, oral, irreversible inhibitor of Bruton’s tyrosine kinase, for the treatment of patients with non-Hodgkin lymphoma, including mantle cell lymphoma, Waldenstrom macroglobulinemia and diffuse large B-cell lymphoma.

Determining effective combinations of immune checkpoint inhibitors for lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Stephen M. Ansell, MD, PhD, of Mayo Clinic, Rochester, MN, discusses the clinical development of combination approaches with immune checkpoint inhibitors for the treatment of patients with non-Hodgkin and Hodgkin lymphoma. Challenges and directions for future trials with this approach are also proposed.

Monoclonal antibody therapies for cutaneous T-cell lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Pier Luigi Zinzani, MD, PhD, of University of Bologna, Bologna, Italy, discusses the clinical development of the anti-CD30 antibody-drug conjugate brentuximab vedotin and the anti-CCR4 antibody mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma.

The changing treatment landscape for non-Hodgkin lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Anton Hagenbeek, MD, PhD, of Academic Medical Center, Amsterdam, The Netherlands, chairs a discussion with Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, NY, and Franck Morschhauser, MD, PhD, of Centre Hospitalier Régional Universitaire de Lille, Lille, France, on new options and new challenges associated with the development of targeted therapies for non-Hodgkin lymphoma. There is a focus on clinical trial design, which must continue to adapt to the increasing number of emerging targeted therapies in order to establish if and how these new approaches can be incorporated into standard clinical care.

Immune checkpoint blockade in non-Hodgkin lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, John Gribben, MD, DSc, FRCPath, FRCP FMedSci, of Barts and The London School of Medicine and Dentistry, London, UK, chairs a discussion with Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, Stephen M. Ansell, MD, PhD, of Mayo Clinic, Rochester, MN, and Nathan H. Fowler, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, on emerging immune targets, such as the interaction between programmed death ligand-1 (PD-L1) and programmed cell death-1 (PD-1), that are demonstrating clinical responses with the use of immune checkpoint inhibitors in patients with non-Hodgkin lymphoma.

Selinexor, selective inhibitor of nuclear export, for non-Hodgkin lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, John Kuruvilla, MD, of Princess Margaret Cancer Centre, Toronto, Canada, discusses the early clinical activity of selinexor, an oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist, for the treatment of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and Richter's transformation.

Duvelisib, dual inhibitor of PI3K delta and PI3K gamma, for indolent non-Hodgkin lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Ian Flinn, MD, of Tennessee Oncology, Nashville, TN, discusses the clinical development of duvelisib, a dual inhibitor of phosphoinositide 3-kinase (PI3K) delta and PI3K gamma, for the treatment of patients with indolent non-Hodgkin lymphoma (iNHL). Duvelisib has demonstrated promising clinical activity in patients with relapsed/refractory iNHL and ongoing clinical trials are investigating duvelisib alone and in combination for this disease.

Approaches to overcome side effects of idelalisib for follicular lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, John Gribben, MD, DSc, FRCPath, FRCP FMedSci, of Barts and The London School of Medicine and Dentistry, London, UK, discusses the efficacy and safety of idelalisib, a first-in-class selective oral inhibitor of phosphoinositide 3-kinase (PI3K) delta, for the treatment of patients with follicular lymphoma.

TGR-1202, novel PI3K delta inhibitor, for hematological malignancies

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Owen A. O'Connor, MD, PhD, of Columbia University, New York, NY, discusses TGR-1202, a novel phosphoinositide 3-kinase (PI3K) delta inhibitor that is in clinical development for patients with hematological malignancies. Clinical activity and safety profile of TGR-1202 appears to be distinct from other PI3K delta inhibitors.

Therapeutic opportunities for lenalidomide in non-Hodgkin lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Nathan H. Fowler, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the ongoing clinical trials that are investigating the use of lenalidomide, an immunomodulatory drug, as monotherapy or in combination for the treatment of different subtypes of non-Hodgkin lymphoma.

16th International Workshop on Non-Hodgkin Lymphoma

Nice, France

Sep

21–23

2018 Meeting

Location

Hotel Le Meridien
1 Prom. des Anglais, 06046 Nice, France

© 2014 - 2019 World Health Communications Ltd